PFE - Pfizer Charts, Trade Ideas, Earnings, Ratings

TRENDING : Top 50 AAPL (%) BAC (-0.35%) NVDA (%) SPWR (0.18%) TLRY (3.92%) TVIX (2.53%) UGAZ (-8.96%) AZO (0.75%) APA (-1.48%) AMZN (%) NOG (-4.09%) NK (-1.5%) NBEV (%) MDGL (%) JD (%) IWM (%) INPX (-6.35%) IBM (%) GS (%) GILD (%) FTSV (%) FSLR (%) FB (%) EYEG (%) DIS (%)

Next Earnings Date : 1/28/2020

PFE - Pfizer

$40.51 -0.1[%]

15 mins delayed data

People also watch : LLY | AZN | JNJ | BMY | NVS | ABT

+Watchlist

13 StockHoot Traders following this.
Analyst Ratings | Earnings

Previous Close	$40.61	Open	$40.57
Volume	10.87M	Market Cap	225.073B
Yield	0.0354%	Last Dividend	$1.44

Day

52 Week

Cannabis Media Company The Fresh Toast E...	1:48 PM
The Fresh Toast, a media company focusing on cannabis and other topics, announced Friday that it has entered cash positive territory following the sig...

Thinking about buying stock in Advanced ...	9:31 AM
/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMD, CGC, FIT, PFE, and SNAP. To see how InvestorsObserver's proprietary scori...

Growth Differentiation Factor 8, Pipelin...	8:27 AM
DUBLIN--(BUSINESS WIRE)--The "Growth Differentiation Factor 8 - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's of...

Glaxo, Pfizer Executives Out of Step on ...	01/16/20
(Bloomberg) -- U.K. drugmaker GlaxoSmithKline Plc hasn???t made plans to pursue an initial public offering of the consumer-health company it set up wi...

Pfizer Eyes IPO of Glaxo Consumer Ventur...	01/15/20
(Bloomberg) -- Pfizer Inc. is planning an initial public offering of its consumer-health joint venture with GlaxoSmithKline Plc in three to four years...

Watch Pfizer CEO Albert Bourla's first T...	01/14/20
Albert Bourla, Pfizer chairman and CEO, sits down with CNBC's Meg Tirrell at the J.P. Morgan health care conference to discuss his first year on the j...

Biogen Acquires Early-Stage CNS Drug Fro...	01/14/20
Biogen (BIIB) signs deals with Pfizer to acquire rights to a CNS candidate and develop it as potential therapy to treat certain symptoms/disorders rel...

Insilico enters into research collaborat...	01/14/20
NEW YORK, Jan. 14, 2020 /PRNewswire/ -- Insilico Medicine is pleased to announce that it has entered into a research collaboration with Pfizer Inc. (N...

3 Big Stock Charts for Tuesday: Pfizer, ...	01/14/20
Tuesday's big stock charts focus on three value plays that have rallied nicely of late ??? and could have more upside ahead.

Genome & Company annonce un accord d'app...	01/14/20
-- Partenariat clinique combinant les phases 1/1b dans un essai clinique avec le GEN-001 de Genome & Company, th??rapie immuno-oncologique bas??e sur ...

ANALYST RATINGS

4 analyst ratings (Last 6 months)

25.00 %

Strong Buy + Buy

Price Target (PT)

Strong Buy rating	01/07/20
RBC Capital initiates coverage with Outperform rating and announces Price Target of $46.00

Hold rating	10/17/19
and announces Price Target of $37.00

Hold rating	08/28/19
DZ Bank upgrades from Sell to Hold rating and announces Price Target of $36.00

Hold rating	08/27/19
Morgan Stanley maintains Equal-Weight rating and lowers Price Target from $40.00 to $38.00

EARNINGS

Date	2019-10-29 (BMO)	Est. (EPS/Rev.)	$0.62/ 12.26B
Actual (EPS/Rev.)	$0.75/ $12.68 B	EPS (TTM)	2.91

TRADERS TRACKING $PFE

Service Name	Trader	% Success
Biotech Fund	Scientia Equity Research	100.00 %	Subscribe
Tech Trades	Ravi	91.00 %	Follow
Big Data Kornacki & Zhou	Zhou Academy	86.00 %	Subscribe
Write put options!	R. belegger	84.00 %	Subscribe
Exegesis	jonathan taylor	70.00 %	Subscribe

SHOW ALL TRADERS

About Us

Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.

Product Types

Strategies

Follow Us

Secure Payments

We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.